FF 10101 01
Alternative Names: FF 10101-01; FF-10101; FF-10101 succinateLatest Information Update: 13 Jun 2024
Price :
$50 *
At a glance
- Originator FUJIFILM Corporation
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia
Most Recent Events
- 05 Apr 2024 Pharmacodynamics data from a preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 08 Apr 2022 Pharmacodynamics data from preclinical trials in Acute myeloid leukaemia presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 04 Jun 2021 Efficacy, adverse event and pharmacokinetics data from a phase I/IIa trial in Acute myeloid leukaemia presented at the 57th Annual Meeting of the American Society of Clinical Oncology (ASCO-2021)